We report significantly higher EZH2 mRNA and protein expression levels in adverse-prognosis U-CLL cases compared to more indolent cases with mutated immunoglobulin heavy variable genes (M-CLL). Here, EZH2 is linked to B-cell chronic lymphocytic leukemia.